A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
Launched by PEKING UNION MEDICAL COLLEGE HOSPITAL · Oct 7, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new imaging agent called 68Ga-DOTA-TATE-RGD, which is designed to help doctors detect certain types of tumors more effectively. Specifically, it targets tumors that have specific markers known as somatostatin receptor 2 (SSTR2) and integrin αvβ3. The trial aims to improve the diagnosis and treatment of iodine-resistant thyroid cancer, meningioma, and neuroendocrine tumors (NETs). By using this advanced imaging method, researchers hope to provide a clearer picture of these tumors, which could lead to better care for patients.
To be eligible for this trial, participants should have a confirmed diagnosis of one of the cancers being studied and must undergo specific imaging tests within a week of joining the trial. They also need to provide written consent to participate. Participants can expect to receive the new imaging agent and to be monitored closely by the research team throughout the study. It's important to note that individuals with known allergies to the study medication or certain medical conditions that might affect their ability to participate may not be eligible. This trial is currently recruiting participants of all genders, aged between 65 and 87, who have been diagnosed with these specific types of tumors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • histologically confirmed various cancer patients;
- • 68Ga-TATE-RGD and 18F-FDG PET/CT within a week;
- • signed written consent.
- Exclusion Criteria:
- • known allergy against TATE-RGD;
- • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
About Peking Union Medical College Hospital
Peking Union Medical College Hospital (PUMCH) is a prestigious medical institution and a leading research facility located in Beijing, China. Affiliated with the Chinese Academy of Medical Sciences, PUMCH is renowned for its commitment to advancing healthcare through innovative clinical research and high-quality patient care. The hospital plays a pivotal role in the development and execution of clinical trials across various medical disciplines, focusing on improving treatment outcomes and enhancing medical knowledge. With a multidisciplinary team of experts and state-of-the-art facilities, PUMCH is dedicated to contributing to global health advancements and fostering collaborations in the medical research community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported